- Home
- CGTX vs AARD Comparison
CGTX vs AARD Comparison
Compare CGTX & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGTX | AARD |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.5M | 85.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CGTX | AARD |
|---|---|---|
| Price | $1.31 | $5.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $3.33 | ★ $15.29 |
| AVG Volume (30 Days) | ★ 1.0M | 139.9K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $3.35 |
| 52 Week High | $3.83 | $17.94 |
Technical Indicators
Market Signals| Indicator | CGTX | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 61.35 | 50.01 |
| Support Level | $1.29 | $4.74 |
| Resistance Level | $1.54 | $6.01 |
| Average True Range (ATR) | 0.10 | 0.42 |
| MACD | 0.02 | 0.16 |
| Stochastic Oscillator | 83.88 | 69.95 |
Price Performance
Historical ComparisonAbout CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.